REIT - Office
Compare Stocks
5 / 10Stock Comparison
NYC vs WELL vs VTR vs CMCT vs GMRE
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
REIT - Healthcare Facilities
REIT - Office
REIT - Healthcare Facilities
NYC vs WELL vs VTR vs CMCT vs GMRE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | REIT - Office | REIT - Healthcare Facilities | REIT - Healthcare Facilities | REIT - Office | REIT - Healthcare Facilities |
| Market Cap | $20M | $149.25B | $41.15B | $6M | $94M |
| Revenue (TTM) | $39M | $11.63B | $6.13B | $117M | $148M |
| Net Income (TTM) | $-21M | $1.43B | $260M | $-39M | $2M |
| Gross Margin | 6.2% | 39.1% | -4.3% | -10.3% | 68.8% |
| Operating Margin | -168.6% | 4.4% | 13.4% | 7.1% | 24.9% |
| Forward P/E | — | 78.4x | 118.0x | — | 595.7x |
| Total Debt | $403M | $21.38B | $13.22B | $510M | $654M |
| Cash & Equiv. | $10M | $5.03B | $741M | $15M | $7M |
NYC vs WELL vs VTR vs CMCT vs GMRE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| American Strategic … (NYC) | 100 | 7.6 | -92.4% |
| Welltower Inc. (WELL) | 100 | 370.3 | +270.3% |
| Ventas, Inc. (VTR) | 100 | 210.0 | +110.0% |
| Creative Media & Co… (CMCT) | 100 | 0.0 | -100.0% |
| Global Medical REIT… (GMRE) | 100 | 54.2 | -45.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NYC vs WELL vs VTR vs CMCT vs GMRE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NYC lags the leaders in this set but could rank higher in a more targeted comparison.
WELL carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 35.8%, EPS growth -11.5%, 3Y rev CAGR 22.7%
- 223.1% 10Y total return vs GMRE's 308.1%
- Lower volatility, beta 0.13, Low D/E 49.5%, current ratio 5.34x
- 35.8% FFO/revenue growth vs CMCT's -6.3%
VTR is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 0.01, yield 2.1%, current ratio 0.96x
- Beta 0.01 vs CMCT's 1.20, lower leverage
CMCT ranks third and is worth considering specifically for dividends.
- 100.0% yield, vs GMRE's 63.5%, (1 stock pays no dividend)
GMRE is the clearest fit if your priority is income & stability.
- Dividend streak 5 yrs, beta 0.48, yield 63.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.8% FFO/revenue growth vs CMCT's -6.3% | |
| Value | Lower P/E (78.4x vs 595.7x) | |
| Quality / Margins | 12.3% margin vs NYC's -53.6% | |
| Stability / Safety | Beta 0.01 vs CMCT's 1.20, lower leverage | |
| Dividends | 100.0% yield, vs GMRE's 63.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +42.7% vs CMCT's -99.0% | |
| Efficiency (ROA) | 2.3% ROA vs NYC's -4.7%, ROIC 0.5% vs -15.8% |
NYC vs WELL vs VTR vs CMCT vs GMRE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NYC vs WELL vs VTR vs CMCT vs GMRE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
WELL leads in 2 of 6 categories
CMCT leads 1 • NYC leads 0 • VTR leads 0 • GMRE leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — WELL and GMRE each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
WELL is the larger business by revenue, generating $11.6B annually — 295.0x NYC's $39M. WELL is the more profitable business, keeping 12.3% of every revenue dollar as net income compared to NYC's -53.6%. On growth, WELL holds the edge at +40.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $39M | $11.6B | $6.1B | $117M | $148M |
| EBITDAEarnings before interest/tax | -$53M | $2.8B | $2.3B | $35M | $95M |
| Net IncomeAfter-tax profit | -$21M | $1.4B | $260M | -$39M | $2M |
| Free Cash FlowCash after capex | -$13M | $2.5B | $1.4B | -$15M | $19M |
| Gross MarginGross profit ÷ Revenue | +6.2% | +39.1% | -4.3% | -10.3% | +68.8% |
| Operating MarginEBIT ÷ Revenue | -168.6% | +4.4% | +13.4% | +7.1% | +24.9% |
| Net MarginNet income ÷ Revenue | -53.6% | +12.3% | +4.2% | -33.4% | +1.7% |
| FCF MarginFCF ÷ Revenue | -33.4% | +21.9% | +22.4% | -12.9% | +12.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +40.3% | +22.0% | +3.6% | +18.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.0% | +22.5% | 0.0% | +97.5% | -166.2% |
Valuation Metrics
CMCT leads this category, winning 2 of 6 comparable metrics.
Valuation Metrics
At 115.3x trailing earnings, GMRE trades at a 28% valuation discount to VTR's 160.3x P/E. On an enterprise value basis, GMRE's 8.3x EV/EBITDA is more attractive than WELL's 66.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $20M | $149.2B | $41.1B | $6M | $94M |
| Enterprise ValueMkt cap + debt − cash | $413M | $165.6B | $53.6B | $500M | $741M |
| Trailing P/EPrice ÷ TTM EPS | -0.14x | 153.25x | 160.26x | -0.10x | 115.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 78.42x | 118.01x | — | 595.67x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 66.40x | 24.31x | 14.15x | 8.35x |
| Price / SalesMarket cap ÷ Revenue | 0.33x | 13.99x | 7.05x | 0.05x | 0.68x |
| Price / BookPrice ÷ Book value/share | 0.23x | 3.35x | 3.18x | 0.02x | 0.17x |
| Price / FCFMarket cap ÷ FCF | — | 52.41x | 31.25x | — | — |
Profitability & Efficiency
WELL leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
WELL delivers a 3.5% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-30 for NYC. WELL carries lower financial leverage with a 0.49x debt-to-equity ratio, signaling a more conservative balance sheet compared to NYC's 4.71x. On the Piotroski fundamental quality scale (0–9), WELL scores 7/9 vs CMCT's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -29.6% | +3.5% | +2.1% | -13.4% | +0.5% |
| ROA (TTM)Return on assets | -4.7% | +2.3% | +1.0% | -4.5% | +0.2% |
| ROICReturn on invested capital | -15.8% | +0.5% | +2.5% | +0.8% | +2.0% |
| ROCEReturn on capital employed | -20.8% | +0.6% | +3.2% | +1.1% | +5.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 6 | 2 | 4 |
| Debt / EquityFinancial leverage | 4.71x | 0.49x | 1.05x | 1.91x | 1.18x |
| Net DebtTotal debt minus cash | $393M | $16.3B | $12.5B | $494M | $647M |
| Cash & Equiv.Liquid assets | $10M | $5.0B | $741M | $15M | $7M |
| Total DebtShort + long-term debt | $403M | $21.4B | $13.2B | $510M | $654M |
| Interest CoverageEBIT ÷ Interest expense | -6.22x | 0.26x | 1.40x | 0.03x | 1.14x |
Total Returns (Dividends Reinvested)
WELL leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WELL five years ago would be worth $30,234 today (with dividends reinvested), compared to $402 for CMCT. Over the past 12 months, WELL leads with a +42.7% total return vs CMCT's -99.0%. The 3-year compound annual growth rate (CAGR) favors WELL at 42.5% vs CMCT's -65.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.0% | +14.3% | +12.6% | -98.1% | +6.9% |
| 1-Year ReturnPast 12 months | -30.7% | +42.7% | +33.9% | -99.0% | +0.1% |
| 3-Year ReturnCumulative with dividends | -6.0% | +189.5% | +94.2% | -95.9% | +5.6% |
| 5-Year ReturnCumulative with dividends | -88.1% | +202.3% | +74.8% | -96.0% | -21.4% |
| 10-Year ReturnCumulative with dividends | -93.8% | +223.1% | +65.0% | -59.4% | +308.1% |
| CAGR (3Y)Annualised 3-year return | -2.1% | +42.5% | +24.8% | -65.5% | +1.8% |
Risk & Volatility
Evenly matched — NYC and VTR each lead in 1 of 2 comparable metrics.
Risk & Volatility
NYC is the less volatile stock with a -0.26 beta — it tends to amplify market swings less than CMCT's 1.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTR currently trades 97.8% from its 52-week high vs CMCT's 0.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.26x | 0.13x | 0.01x | 1.20x | 0.48x |
| 52-Week HighHighest price in past year | $16.30 | $219.59 | $88.50 | $1441.00 | $39.93 |
| 52-Week LowLowest price in past year | $7.03 | $142.65 | $61.76 | $3.60 | $29.05 |
| % of 52W HighCurrent price vs 52-week peak | +49.6% | +97.0% | +97.8% | +0.5% | +89.5% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 60.2 | 56.2 | 21.2 | 52.7 |
| Avg Volume (50D)Average daily shares traded | 2K | 2.6M | 3.4M | 3.9M | 130K |
Analyst Outlook
Evenly matched — CMCT and GMRE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: WELL as "Buy", VTR as "Buy", GMRE as "Buy". Consensus price targets imply 11.9% upside for GMRE (target: $40) vs 4.9% for VTR (target: $91). For income investors, CMCT offers the higher dividend yield at 100.00% vs WELL's 1.30%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — | Buy |
| Price TargetConsensus 12-month target | — | $226.50 | $90.80 | — | $40.00 |
| # AnalystsCovering analysts | — | 34 | 32 | — | 22 |
| Dividend YieldAnnual dividend ÷ price | — | +1.3% | +2.1% | +100.0% | +63.5% |
| Dividend StreakConsecutive years of raises | 0 | 2 | 1 | 0 | 5 |
| Dividend / ShareAnnual DPS | — | $2.76 | $1.86 | $23.89 | $22.70 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.1% | 0.0% | 0.0% | +2.8% | 0.0% |
WELL leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). CMCT leads in 1 (Valuation Metrics). 3 tied.
NYC vs WELL vs VTR vs CMCT vs GMRE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NYC or WELL or VTR or CMCT or GMRE a better buy right now?
For growth investors, Welltower Inc.
(WELL) is the stronger pick with 35. 8% revenue growth year-over-year, versus -6. 3% for Creative Media & Community Trust Corporation (CMCT). Global Medical REIT Inc. (GMRE) offers the better valuation at 115. 3x trailing P/E (595. 7x forward), making it the more compelling value choice. Analysts rate Welltower Inc. (WELL) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NYC or WELL or VTR or CMCT or GMRE?
On trailing P/E, Global Medical REIT Inc.
(GMRE) is the cheapest at 115. 3x versus Ventas, Inc. at 160. 3x. On forward P/E, Welltower Inc. is actually cheaper at 78. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NYC or WELL or VTR or CMCT or GMRE?
Over the past 5 years, Welltower Inc.
(WELL) delivered a total return of +202. 3%, compared to -96. 0% for Creative Media & Community Trust Corporation (CMCT). Over 10 years, the gap is even starker: GMRE returned +308. 1% versus NYC's -93. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NYC or WELL or VTR or CMCT or GMRE?
By beta (market sensitivity over 5 years), American Strategic Investment Co.
(NYC) is the lower-risk stock at -0. 26β versus Creative Media & Community Trust Corporation's 1. 20β — meaning CMCT is approximately -556% more volatile than NYC relative to the S&P 500. On balance sheet safety, Welltower Inc. (WELL) carries a lower debt/equity ratio of 49% versus 5% for American Strategic Investment Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — NYC or WELL or VTR or CMCT or GMRE?
By revenue growth (latest reported year), Welltower Inc.
(WELL) is pulling ahead at 35. 8% versus -6. 3% for Creative Media & Community Trust Corporation (CMCT). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -94. 6% for Global Medical REIT Inc.. Over a 3-year CAGR, WELL leads at 22. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NYC or WELL or VTR or CMCT or GMRE?
Welltower Inc.
(WELL) is the more profitable company, earning 8. 8% net margin versus -228. 3% for American Strategic Investment Co. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMRE leads at 23. 6% versus -196. 9% for NYC. At the gross margin level — before operating expenses — GMRE leads at 78. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NYC or WELL or VTR or CMCT or GMRE more undervalued right now?
On forward earnings alone, Welltower Inc.
(WELL) trades at 78. 4x forward P/E versus 595. 7x for Global Medical REIT Inc. — 517. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMRE: 11. 9% to $40. 00.
08Which pays a better dividend — NYC or WELL or VTR or CMCT or GMRE?
In this comparison, CMCT (100.
0% yield), GMRE (63. 5% yield), VTR (2. 1% yield), WELL (1. 3% yield) pay a dividend. NYC does not pay a meaningful dividend and should not be held primarily for income.
09Is NYC or WELL or VTR or CMCT or GMRE better for a retirement portfolio?
For long-horizon retirement investors, Ventas, Inc.
(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Both have compounded well over 10 years (VTR: +65. 0%, CMCT: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NYC and WELL and VTR and CMCT and GMRE?
Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NYC is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; CMCT is a small-cap income-oriented stock; GMRE is a small-cap income-oriented stock. WELL, VTR, CMCT, GMRE pay a dividend while NYC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.